Key facts
| Price (PPV) | 129.80 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | irbesartanhydrchlorothiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA04 |
| Manufacturer | NOVOPHARMA |
| Presentation | Boite de 30 |
| Hospital price | 81.10 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement de l'hypertension artérielle essentielle lorsque l'effet d'une monothérapie reste insuffisant. Traitement initial en cas d'hypertension prononcée, lorsqu'un contrôle rapide de la pression artérielle (en termes de jours ou de semaines) est de première importance clinique. Nature du Produit Médicament
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Co-Arapro 150 mg / 12.5 mg (ZENITH PHARMA) contains the same active substance as Novortan Plus 150 mg / 12.5 mg (Irbesartan | Hydrchlorothiazide) at the same strength, but in a different pack: Boite de 10 at 50.30 MAD, i.e. 5.03 MAD per unit against 4.33 MAD for Novortan Plus 150 mg / 12.5 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
Same pack size
| Product | Manufacturer | Pack | PPV | Unit price | Difference |
|---|---|---|---|---|---|
| Co-Arapro 150 mg / 12.5 mg | ZENITH PHARMA | Boite de 30 | 129.80 MAD | 4.33 / unit | — |
| Coavacor 150 mg / 12.5 mg | POLYMEDIC | Boite de 30 | 129.80 MAD | 4.33 / unit | — |
| Irphi Plus 150 mg / 12.5 mg | PHI | Boite de 30 | 129.80 MAD | 4.33 / unit | — |
Other pack sizes
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Co-Arapro 150 mg / 12.5 mg | ZENITH PHARMA | Boite de 10 | 50.30 MAD | 5.03 / unit |
| Co-Icard 150 mg / 12.5 mg | COOPER PHARMA | Boite de 14 | 69.50 MAD | 4.96 / unit |
| Co-Irvel 150 mg / 12.5 mg | AFRIC-PHAR | Boite de 14 | 69.50 MAD | 4.96 / unit |
| Co-Avepro 150 mg / 12.5 mg | SOTHEMA | Boite de 14 | 70 MAD | 5 / unit |
| Co-Icard 150 mg / 12.5 mg | COOPER PHARMA | Boite de 28 | 124 MAD | 4.43 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Novortan Plus 150 mg / 12.5 mg
Novortan Plus 150 mg / 12.5 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by NOVOPHARMA and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Novortan Plus 150 mg / 12.5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Novortan Plus 150 mg / 12.5 mg
Answers to common questions from Moroccan patients about this drug.